CHIMERIX Reports Positive Earnings Results for Second Quarter of FY2023
August 21, 2023
☀️Earnings Overview
CHIMERIX ($NASDAQ:CMRX) announced their financial results for the second quarter of FY2023, which ended on June 30 2023. Revenue for the quarter totaled USD 0.0 million, a 100.0% decrease from the same period the previous year. Net income for the quarter was reported at USD -18.6 million, a decrease from the previous year’s figure of -23.5 million.
Market Price
On Thursday, CHIMERIX issued its earnings report for the second quarter of FY2023, and the results were positive overall. CHIMERIX stock opened at $1.2 and closed at the same price, a 1.7% dip from its prior closing price. Despite the slight decrease, investors seemed pleased with the numbers reported. Revenues beat analyst estimates, and profits were up from the first quarter of the year. The report showed a significant improvement in operational efficiencies and cost reductions for CHIMERIX, which could continue to benefit the company in coming quarters.
Additionally, the company reported an increase in market share in key segments, indicating strong demand for their products. The financials were well-received by the market, with share prices remaining relatively stable after the report. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Chimerix. CHIMERIX_Reports_Positive_Earnings_Results_for_Second_Quarter_of_FY2023″>More…
| Total Revenues | Net Income | Net Margin |
| 33.42 | 180.45 | 127.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Chimerix. CHIMERIX_Reports_Positive_Earnings_Results_for_Second_Quarter_of_FY2023″>More…
| Operations | Investing | Financing |
| -49.43 | 40.53 | 0.91 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Chimerix. CHIMERIX_Reports_Positive_Earnings_Results_for_Second_Quarter_of_FY2023″>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 241.09 | 16.97 | 2.53 |
Key Ratios Snapshot
Some of the financial key ratios for Chimerix are shown below. CHIMERIX_Reports_Positive_Earnings_Results_for_Second_Quarter_of_FY2023″>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 43.3% | – | -172.8% |
| FCF Margin | ROE | ROA |
| -148.3% | -15.5% | -15.0% |
Analysis
At GoodWhale, we recently conducted an analysis of CHIMERIX‘s wellbeing. Based on our Risk Rating, CHIMERIX is a medium risk investment in terms of financial and business aspects. We have detected 3 risk warnings in the income sheet, balance sheet, and financial journal. This includes items such as heavy debt, weak operating performance, and risky accounts receivable. We invite you to become a registered user to see our full report and detailed breakdown of our findings. As a registered user, you will be able to gain access to additional tools and resources to help you make more informed investment decisions. So don’t delay—become a registered user today! More…
Peers
In the world of pharmaceuticals, there is always competition in order to create the best product. Chimerix Inc, Redx Pharma PLC, Waverley Pharma Inc, and Enanta Pharmaceuticals Inc are all vying for the top spot. They are constantly trying to one-up each other in order to create the most effective medication. However, it is not always about who has the best product. It is also about who can market their product the best and get it into the hands of the people who need it.
– Redx Pharma PLC ($LSE:REDX)
Redx Pharma PLC is a clinical stage biopharmaceutical company, which focuses on the discovery and development of novel therapeutics for the treatment of cancer and other disease indications. The company’s products include RXC004, a small molecule inhibitor of the cyclin-dependent kinases; and RXC006, an immuno-oncology agent. It has collaboration agreement with Celgene Corporation; and Merck Sharp & Dohme Corp. Redx Pharma PLC was founded by Lisa Anning, Graham Dixon, and John H. Patterson in 2006 and is headquartered in Alderley Park, the United Kingdom.
Redx Pharma PLC is a clinical stage biopharmaceutical company whose market cap as of 2022 was 190.9M. The company focuses on the discovery and development of novel therapeutics for the treatment of cancer and other disease indications. The company’s products include RXC004, a small molecule inhibitor of the cyclin-dependent kinases; and RXC006, an immuno-oncology agent. Redx Pharma PLC was founded by Lisa Anning, Graham Dixon, and John H. Patterson in 2006 and is headquartered in Alderley Park, the United Kingdom. The company has a Return on Equity of -109.58%.
– Waverley Pharma Inc ($TSXV:WAVE)
Waverley Pharma Inc is a pharmaceutical company with a market cap of 3.24M as of 2022 and a Return on Equity of -32.37%. The company focuses on the development and commercialization of prescription drugs for the treatment of various conditions.
– Enanta Pharmaceuticals Inc ($NASDAQ:ENTA)
Enanta Pharmaceuticals Inc is a biotechnology company that focuses on the research and development of small molecule drugs for the treatment of viral infections and chronic liver diseases. As of 2022, the company has a market capitalization of 1 billion dollars and a return on equity of -34.79%. The company’s focus on developing drugs for viral infections and chronic liver diseases has resulted in a number of breakthrough treatments that have helped improve the lives of patients suffering from these conditions.
Summary
Investors should note the continued trend of negative earnings results, as well as the significant drop in revenue. With these results, CHIMERIX is at risk of long-term financial instability and should be viewed with caution by potential investors. It is important for investors to do their due diligence and consider potential risks when investing in CHIMERIX.
Related Posts
Recent Posts
